Effectiveness of RCTs Pooling Evidence on Mesenchymal Stem Cell (MSC) Therapeutic Applications During COVID-19 Epidemic: A Systematic Review

References

• Shi L, Huang H, Lu X, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled Phase 2 trial. Signal Transduct Target Ther. 2021;6:58.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Coronavirus Disease (COVID-19) Situation Reports. World Health Organization; 2022. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed November 27, 2022.
   Google Scholar
• Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost JTH. 2020;18:844–847.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422.
   PubMed Web of Science ®Google Scholar
• Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–473.
   PubMed Web of Science ®Google Scholar
• Morens DM, Fauci AS. Emerging pandemic diseases: how we got to COVID-19. Cell. 2020;182:1077–1092.
   PubMed Web of Science ®Google Scholar
• Lal A, Erondu NA, Heymann DL, Gitahi G, Yates R. Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage. Lancet Lond Engl. 2021;397:61–67.
   PubMed Web of Science ®Google Scholar
• Rubin EJ, Baden LR, Morrissey S. Audio interview: studying potential covid-19 therapies. N Engl J Med. 2020;382:e72.
   PubMedGoogle Scholar
• Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523.
   PubMed Web of Science ®Google Scholar
• Yang Q, Zhou Y, Ai J, et al. Collaborated effort against SARS‐CoV‐2 outbreak in China. Clin Transl Med. 2020;10:13–16.
   PubMed Web of Science ®Google Scholar
• Xu X, Jiang W, Chen L, et al. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: an exploratory clinical trial. Clin Transl Med. 2021;11:e297.
   PubMed Web of Science ®Google Scholar
• Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
   PubMed Web of Science ®Google Scholar
• Sun Y, Koh V, Marimuthu K, et al. Epidemiological and Clinical Predictors of COVID-19. Clin Infect Dis off Publ Infect Dis Soc Am. 2020;71:786–792.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (covid-19): a review. JAMA. 2020;324:782–793.
   PubMed Web of Science ®Google Scholar
• Xu X-W, Wu -X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
   PubMed Web of Science ®Google Scholar
• Xu M, Wang D, Wang H, et al. COVID-19 diagnostic testing: technology perspective. Clin Transl Med. 2020;10:e158.
   PubMed Web of Science ®Google Scholar
• Hossein-Khannazer N, Shpichka A, Shokoohian B, et al. Novel therapeutic approaches for treatment of COVID-19. J Mol Med Berl Ger. 2020;98:789–803.
   PubMed Web of Science ®Google Scholar
• Ramezankhani R, Solhi R, Memarnejadian A, et al. Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. Int J Antimicrob Agents. 2020;56:106208.
   PubMed Web of Science ®Google Scholar
• Qin H, Zhao A. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell. 2020;11:707–722.
   PubMed Web of Science ®Google Scholar
• Moll G, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk H-D, Reinke P. MSC Therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy. Front Immunol. 2020;11:1091.
   PubMed Web of Science ®Google Scholar
• Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–469.
   PubMed Web of Science ®Google Scholar
• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19:149–150.
   PubMed Web of Science ®Google Scholar
• Atala A, Henn A, Lundberg M, et al. Regen med therapeutic opportunities for fighting COVID‐19. Stem Cells Transl Med. 2020;10:5–13.
   PubMed Web of Science ®Google Scholar
• Group RC. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384:693–704.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578.
   PubMed Web of Science ®Google Scholar
• Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369:eabc8511.
   PubMed Web of Science ®Google Scholar
• Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. 2020;5:eabd7114.
   PubMed Web of Science ®Google Scholar
• Song J-W, Zhang C, Fan X, et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020;11:3410.
   PubMed Web of Science ®Google Scholar
• Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current State of the Science. Immunity. 2020;52:910–941.
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323:2052–2059.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324:460–470.
   PubMed Web of Science ®Google Scholar
• Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92:814–818.
   PubMed Web of Science ®Google Scholar
• FDA. Pfizer-Biontech COVID-19 Vaccines. FDA; 2023.
   Google Scholar
• FDA. Moderna COVID-19 Vaccines. FDA; 2023.
   Google Scholar
• FDA. Janssen COVID-19 Vaccine. FDA; 2023.
   Google Scholar
• FDA. Novavax COVID-19 Vaccine, Adjuvanted. FDA; 2022.
   Google Scholar
• Beigel JH. What is the role of remdesivir in patients with COVID-19? Curr Opin Crit Care. 2021;27:487–492.
   PubMed Web of Science ®Google Scholar
• Bose S, Adapa S, Aeddula NR, et al. Medical management of COVID-19: evidence and experience. J Clin Med Res. 2020;12:329–343.
   PubMedGoogle Scholar
• Rogers CJ, Harman RJ, Bunnell BA, et al. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. J Transl Med. 2020;18:1–19.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang Q, Peng W, et al. Efficacy and safety of mesenchymal stem cells for the treatment of patients infected with COVID-19: a systematic review and meta-analysis protocol. BMJ Open. 2020;10:e042085.
   PubMedGoogle Scholar
• Bamba C, Singh SP, Choudhury S. Can mesenchymal stem cell therapy be the interim management of COVID-19? Drug Discov Ther. 2020;14:139–142.
   PubMed Web of Science ®Google Scholar
• Shahsavari A, Weeratunga P, Ovchinnikov DA, Whitworth DJ. Pluripotency and immunomodulatory signatures of canine induced pluripotent stem cell-derived mesenchymal stromal cells are similar to harvested mesenchymal stromal cells. Sci Rep. 2021;11:3486.
   PubMed Web of Science ®Google Scholar
• Damayanti RH, Rusdiana T, Wathoni N. Mesenchymal stem cell secretome for dermatology application: a review. Clin Cosmet Investig Dermatol. 2021;14:1401–1412.
   PubMed Web of Science ®Google Scholar
• Atluri S. Safety and effectiveness of intravascular mesenchymal stem cells to treat organ failure and possible application in COVID-19 Complications. Pain Physician. 2020;4:S391–S420.
   Google Scholar
• Singh B, Mal G, Verma V, et al. Stem cell therapies and benefaction of somatic cell nuclear transfer cloning in COVID-19 era. Stem Cell Res Ther. 2021;12:1–16.
   PubMed Web of Science ®Google Scholar
• Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal Stem Cells for Regenerative Medicine. Cells. 2019;8:886.
   PubMed Web of Science ®Google Scholar
• Kolanko E, Mazurski A, Czekaj P. Potential therapeutic application of mesenchymal stem cells in COVID-19 complications. Med Pr. 2021;72:693–700.
   PubMed Web of Science ®Google Scholar
• Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012;10:709–716.
   PubMed Web of Science ®Google Scholar
• Farkhad NK, Mahmoudi A, Mahdipour E. How similar are human mesenchymal stem cells derived from different origins? A review of comparative studies. Curr Stem Cell Res Ther. 2021;16:980–993.
   PubMed Web of Science ®Google Scholar
• Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization of cells with osteogenic potential from human marrow. Bone. 1992;13:81–88.
   PubMed Web of Science ®Google Scholar
• Yousefi Dehbidi M, Goodarzi N, Azhdari MH, Doroudian M. Mesenchymal stem cells and their derived exosomes to combat Covid–19. Rev Med Virol. 2022;32:e2281.
   PubMed Web of Science ®Google Scholar
• Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells Dayt Ohio. 2017;35:851–858.
   PubMed Web of Science ®Google Scholar
• Park WB, Kim SY, Lee SH, Kim H-W, Park J-S, Hyun JK. The effect of mesenchymal stem cell transplantation on the recovery of bladder and hindlimb function after spinal cord contusion in rats. BMC Neurosci. 2010;11:119.
   PubMed Web of Science ®Google Scholar
• Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med. 2011;9:52.
   PubMed Web of Science ®Google Scholar
• Zhu Y-G, Shi -M-M, Monsel A, et al. Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study. Stem Cell Res Ther. 2022;13:220.
   PubMed Web of Science ®Google Scholar
• Kaffash Farkhad N, Sedaghat A, Reihani H, et al. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful Phase 1, control-placebo group, clinical trial. Stem Cell Res Ther. 2022;13:283.
   PubMed Web of Science ®Google Scholar
• Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21:1019–1024.
   PubMed Web of Science ®Google Scholar
• Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med. 2017;6:1445–1451.
   PubMed Web of Science ®Google Scholar
• Bianco P. “Mesenchymal” stem cells. Annu Rev Cell Dev Biol. 2014;30:677–704.
   PubMed Web of Science ®Google Scholar
• Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–736.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12:383–396.
   PubMed Web of Science ®Google Scholar
• Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25:829–848.
   PubMed Web of Science ®Google Scholar
• Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22:824–833.
   PubMed Web of Science ®Google Scholar
• Caplan H, Olson SD, Kumar A, et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Front Immunol. 2019;10:1645.
   PubMed Web of Science ®Google Scholar
• Moll G, Ankrum JA, Kamhieh-Milz J, et al. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med. 2019;25:149–163.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Davies LC. MSCs-cells with many sides. Cytotherapy. 2018;20:273–278.
   PubMed Web of Science ®Google Scholar
• Mastrolia I, Foppiani EM, Murgia A, et al. Challenges in clinical development of mesenchymal stromal/stem cells: concise review. Stem Cells Transl Med. 2019;8:1135–1148.
   PubMed Web of Science ®Google Scholar
• Harrell CR, Sadikot R, Pascual J, et al. Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives. Stem Cells Int. 2019;2019:25.
   Web of Science ®Google Scholar
• Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–292.e6.
   PubMed Web of Science ®Google Scholar
• Yang J, Petitjean SJL, Koehler M, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. 2020;11:4541.
   PubMed Web of Science ®Google Scholar
• Schäfer R, Spohn G, Bechtel M, et al. Human mesenchymal stromal cells are resistant to SARS-CoV-2 infection under steady-state, inflammatory conditions and in the presence of SARS-CoV-2-infected cells. Stem Cell Rep. 2021;16:419–427.
   PubMed Web of Science ®Google Scholar
• Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216–228.
   PubMed Web of Science ®Google Scholar
• Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3:24–32.
   PubMed Web of Science ®Google Scholar
• Chen J, Hu C, Chen L, et al. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) Infection: a hint for COVID-19 treatment. Engineering. 2020;6:1153–1161.
   Web of Science ®Google Scholar
• Chan MCW, Kuok DIT, Leung CYH, et al. Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci U S A. 2016;113:3621–3626.
   PubMed Web of Science ®Google Scholar
• WHO Working. Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192–e197.
   PubMedGoogle Scholar
• Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7:154–162.
   PubMed Web of Science ®Google Scholar
• Simonson OE, Mougiakakos D, Heldring N, et al. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl Med. 2015;4:1199–1213.
   PubMed Web of Science ®Google Scholar
• Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15:39.
   PubMed Web of Science ®Google Scholar
• Tang L, Jiang Y, Zhu M, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med. 2020;14:664–673.
   PubMed Web of Science ®Google Scholar
• Adas G, Cukurova Z, Yasar KK, et al. The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial. Cell Transplant. 2021;30:09636897211024942.
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Takeuchi S, Iwasawa T, et al. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. Inflamm Regen. 2020;40:14.
   PubMed Web of Science ®Google Scholar
• Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11:361.
   PubMed Web of Science ®Google Scholar
• Monsel A, Hauw-Berlemont C, Mebarki M, et al. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit Care Lond Engl. 2022;26:48.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019;4:22.
   PubMed Web of Science ®Google Scholar
• Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5:172.
   PubMed Web of Science ®Google Scholar
• Laroye C, Gibot S, Huselstein C, Bensoussan D. Mesenchymal stromal cells for sepsis and septic shock: lessons for treatment of COVID-19. STEM CELLS Transl Med. 2020;9:1488–1494.
   PubMed Web of Science ®Google Scholar
• Liau LL, Ruszymah BHI, Ng MH, Law JX. Characteristics and clinical applications of Wharton’s jelly-derived mesenchymal stromal cells. Curr Res Transl Med. 2020;68:5–16.
   PubMed Web of Science ®Google Scholar
• Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev Rep. 2020;16:427–433.
   PubMed Web of Science ®Google Scholar
• Hashemian S-MR, Aliannejad R, Zarrabi M, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021;12:91.
   PubMed Web of Science ®Google Scholar
• Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10:660–673.
   PubMed Web of Science ®Google Scholar
• Can A, Celikkan FT, Cinar O. Umbilical cord mesenchymal stromal cell transplantations: a systemic analysis of clinical trials. Cytotherapy. 2017;19:1351–1382.
   PubMed Web of Science ®Google Scholar
• Patel AN, Vargas V, Revello P, Bull DA. Mesenchymal stem cell population isolated from the subepithelial layer of umbilical cord tissue. Cell Transplant. 2013;22:513–519.
   PubMed Web of Science ®Google Scholar
• Khoury M, Alcayaga-Miranda F, Illanes SE, Figueroa FE. The promising potential of menstrual stem cells for antenatal diagnosis and cell therapy. Front Immunol. 2014;5:205.
   PubMed Web of Science ®Google Scholar
• Wu X, Luo Y, Chen J, et al. Transplantation of human menstrual blood progenitor cells improves hyperglycemia by promoting endogenous progenitor differentiation in type 1 diabetic mice. Stem Cells Dev. 2014;23:1245–1257.
   PubMed Web of Science ®Google Scholar
• Chen L, Qu J, Xiang C. The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine. Stem Cell Res Ther. 2019;10:1.
   PubMed Web of Science ®Google Scholar
• Fathi-Kazerooni M, Tavoosidana G, Taghizadeh-Jahed M, et al. Comparative restoration of acute liver failure by menstrual blood stem cells compared with bone marrow stem cells in mice model. Cytotherapy. 2017;19:1474–1490.
   PubMed Web of Science ®Google Scholar
• Bozorgmehr M, Gurung S, Darzi S, et al. Endometrial and menstrual blood mesenchymal stem/stromal cells: biological properties and clinical application. Front Cell Dev Biol. 2020;8:8.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Jones RJ. Aplastic anaemia. Lancet. 2005;365(9471):1647–1656.
   PubMed Web of Science ®Google Scholar
• Can A, Coskun H. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: what to expect. Stem Cells Transl Med. 2020;9:1287–1302.
   PubMed Web of Science ®Google Scholar
• Wu M, Zhang R, Zou Q, et al. Comparison of the biological characteristics of mesenchymal stem cells derived from the human placenta and umbilical cord. Sci Rep. 2018;8:5014.
   PubMed Web of Science ®Google Scholar
• Yang Q, Liu Q, Xu H, Lu H, Liu S, Li H. Imaging of coronavirus disease 2019: a Chinese expert consensus statement. Eur J Radiol. 2020;127:109008.
   PubMed Web of Science ®Google Scholar
• McKenzie JM, Bossuyt JE, Boutron PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMedGoogle Scholar
• Abdullah M, Pawitan JA, Irawan C, et al. Effectiveness and safety profile of mesenchymal stem cell secretome as a treatment for severe cases of COVID-19: a randomized controlled trial. F1000Research. 2022;11:143.
   Google Scholar
• Aghayan HR, Salimian F, Abedini A, et al. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (Phase I clinical trial): safety profile assessment. Stem Cell Res Ther. 2022;13:365.
   PubMed Web of Science ®Google Scholar
• Araldi RP, Prezoto BC, Gonzaga V, et al. Advanced cell therapy with low tissue factor loaded product NestaCell® does not confer thrombogenic risk for critically ill COVID-19 heparin-treated patients. Biomed Pharmacother. 2022;149:112920.
   PubMedGoogle Scholar
• Karyana M, Djaharuddin I, Rif’ati L, et al. Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial. Stem Cell Res Ther. 2022;13:134.
   PubMed Web of Science ®Google Scholar
• Rebelatto CLK, Senegaglia AC, Franck CL, et al. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Res Ther. 2022;13:122.
   PubMed Web of Science ®Google Scholar
• Sahin AS, Kaya E, Turgut G, Dolay K, Kocatas A. Mesenchymal stem cell therapy in COVID-19 pneumonia: a prospective, randomized clinical research. Turkiye Klin Tip Bilim Derg. 2022;2022:5–13.
   Google Scholar
• Dilogo IH, Aditianingsih D, Sugiarto A, et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial. Stem Cells Transl Med. 2021;10:1279–1287.
   PubMed Web of Science ®Google Scholar
• Shi L, Yuan X, Yao W, et al. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2022;75:103789.
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
   PubMed Web of Science ®Google Scholar